Treatment of erectile dysfunction, which is defined as the inability to achieve and maintain an erection of the penis necessary for successful sexual intercourse. For effective action of Arosio required for Sexual Arousal.
Erosil №2 Composition
active substance: sildenafil;
1 tablet contains sildenafil citrate in terms of 100% sildenafil 100 mg;
excipients: lactose monohydrate, magnesium gluconate; powdered sugar; calcium stearate lemon flavoring; dye tartrazine (E 102).
Erosil №2 Dosage form
Basic physical and chemical properties: tablets of yellow or yellow-brown color interspersed with a notch on one side.
Drugs used to treat erectile dysfunction. ATX code G04B E03.
Mechanism of action. Sildenafil is an oral medication for the treatment of erectile dysfunction. With sexual arousal, the drug restores reduced erectile function by increasing blood flow to the penis.
The physiological mechanism that leads to an erection, including the release of nitric oxide (NO) in the corpora cavernosa during sexual arousal. The released NO activates the enzyme guanylate cyclase, which stimulates an increase in the level of cyclic guanosine monophosphate (cGMP), which, in turn, causes relaxation of the smooth muscles of the corpora cavernosa, promoting blood flow.
Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase 5 (PDE-5) in the corpora cavernosa, where PDE-5 is responsible for the breakdown of cGMP. The effect of sildenafil on erection is peripheral. Sildenafil does not have a direct relaxing effect on isolated human cavernous bodies, but powerfully enhances the relaxing effect of NO on this tissue. When the NO / cGMP metabolic pathway is activated, which occurs during sexual stimulation, inhibition of PDE5 by sildenafil leads to an increase in the level of cGMP in the corpora cavernosa. Thus, in order for sildenafil to cause a pharmacological effect, sexual arousal is necessary.
Impact on pharmacodynamics. In vitro studies have shown that sildenafil is selective for PDE-5, which is actively involved in the process of erection. The effect of sildenafil on PDE-5 is more potent than on other known phosphodiesterases. This effect is 10 times more powerful than the effect on PDE6, which is involved in the processes of phototransformation in the retina. When using the maximum recommended doses, the selectivity of sildenafil to PDE-5 is 80 times higher than its selectivity to PDE1, 700 times higher than that of PDE2, PDE-3, PDE4, PDE7, PDE8, PDE9, PDE10 and PDE11. In particular, the selectivity of sildenafil for PDE-5 is 4000 times higher than its selectivity for PDE-3, a cAMP-specific isoform of PDE, which is involved in the regulation of cardiac contractility.
Erosil №2 Indications
Erosil is recommended for men with erectile dysfunction, which is defined as the inability to achieve or maintain an erection of the penis necessary for successful intercourse.
For effective action Erosil needs sexual arousal.
Hypersensitivity to sildenafil or other components of the drug.
Concomitant use with nitric oxide donors (such as amyl nitrite) or nitrates in any form, since it is known that sildenafil affects the pathways of nitric oxide / cyclic guanosine monophosphate (cGMP) metabolism and potentiates the hypotensive effect of nitrates.
The simultaneous use of PDE-5 inhibitors (including sildenafil) with guanylate cyclase stimulants, such as riociguat, is contraindicated because it can lead to symptomatic hypotension (see Section “Interaction with other medicinal products and other types of interactions”).
Conditions for which sexual activity is not recommended (for example, severe cardiovascular disorders such as unstable angina or severe heart failure).
Loss of vision in one eye due to non-arterial anterior ischemic neuropathy of the optic nerve, regardless of whether this pathology is associated with previous use of PDE-5 inhibitors or not.
The presence of diseases such as severe liver dysfunction, arterial hypotension (blood pressure below 90/50 mm Hg. Art.), Recent stroke or myocardial infarction and known hereditary degenerative retinal diseases such as retinitis pigmentosa ( genetic disorders of PDE of the retina), since the safety of sildenafil has not been investigated in such subgroups of patients.